Latest news with #KaplanFox&KilsheimerLLP
Associated Press
15-05-2025
- Business
- Associated Press
Kaplan Fox is Investigating Potential Securities Law Violations Against Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY - May 15, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Iovance investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024. Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
06-05-2025
- Business
- Associated Press
ICU MEDICAL SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating ICU Medical, Inc. (ICUI) for Possible Securities Law Violations
NEW YORK - May 5, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ICU Medical, Inc. ('ICU Medical' or the 'Company') (NASDAQ: ICUI). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On April 22, 2025, Bloomberg reported that the Federal Drug Administration ('FDA') had issued a Warning Letter to ICU Medical 'regarding unapproved changes to its infusion pumps.' The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company 'made multiple changes to the Medfusion(R) Model 4000 Syringe Infusion Pump and CADD(R) Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,' and that the Company 'failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .' The Warning Letter further states that the pumps are 'adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.' Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
04-05-2025
- Business
- Associated Press
ICUI SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP is Investigating ICU Medical, Inc. (ICUI) for Potential Securities Law Violations
NEW YORK, NY - May 3, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ICU Medical, Inc. ('ICU Medical' or the 'Company') (NASDAQ: ICUI). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On April 22, 2025, Bloomberg reported that the Federal Drug Administration ('FDA') had issued a Warning Letter to ICU Medical 'regarding unapproved changes to its infusion pumps.' The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company 'made multiple changes to the Medfusion(R) Model 4000 Syringe Infusion Pump and CADD(R) Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,' and that the Company 'failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .' The Warning Letter further states that the pumps are 'adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.' Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
02-05-2025
- Business
- Associated Press
ICU MEDICAL ALERT: Kaplan Fox & Kilsheimer LLP is Investigating ICU Medical, Inc. (ICUI) for Potential Securities Law Violations
NEW YORK, NY - May 1, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ICU Medical, Inc. ('ICU Medical' or the 'Company') (NASDAQ: ICUI). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On April 22, 2025, Bloomberg reported that the Federal Drug Administration ('FDA') had issued a Warning Letter to ICU Medical 'regarding unapproved changes to its infusion pumps.' The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company 'made multiple changes to the Medfusion(R) Model 4000 Syringe Infusion Pump and CADD(R) Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,' and that the Company 'failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .' The Warning Letter further states that the pumps are 'adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.' Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
Associated Press
30-04-2025
- Business
- Associated Press
ICU MEDICAL Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK, NY - April 30, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ICU Medical, Inc. ('ICU Medical' or the 'Company') (NASDAQ: ICUI). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On April 22, 2025, Bloomberg reported that the Federal Drug Administration ('FDA') had issued a Warning Letter to ICU Medical 'regarding unapproved changes to its infusion pumps.' The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company 'made multiple changes to the Medfusion(R) Model 4000 Syringe Infusion Pump and CADD(R) Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,' and that the Company 'failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .' The Warning Letter further states that the pumps are 'adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.' Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
